June 12, 2020


Gregory Stoloff

Gregory Stoloff founded SEEK Group – formerly known as PepTcell – in 2004 after a distinguished career in investment banking spanning 20 years, working in a broad range of institutions including Deutsche Bank and UBS.

He initially concentrated on corporate finance and was involved in numerous mergers and acquisitions and structured finance with an emphasis on the healthcare industry, including mergers by GlaxoSmithKline, Aventis and Pfizer. Gregory then moved on to concentrate on project finance and was involved in financings for major pharmaceutical companies such as Roche, Merck and Novartis and across various other sectors. Gregory also has a wealth of experience in advising and working with medical research companies.

Gregory is a qualified Chartered Accountant and has spent many years researching scientific medical issues, specifically related to the immune system. He has also been involved in several publications, recounting research in the peptide space and is listed as an inventor in numerous patents for cancer, HIV, mosquito-borne diseases and influenza.

Gregory has been instrumental in the development of the concepts pursued by SEEK and has been the driving force behind the Group’s continued growth and diversification.

Dr Robin Bannister

Robin Bannister joined the SEEK Group in 2008 when his Company, Biocopea, was acquired by SEEK – then known as PepTcell. Robin focuses on the discovery of novel biology based on existing drugs and drug templates and the subsequent identification and exploitation of high–value, low-risk products. Robin is a successful drug-discovery and development entrepreneur. Before founding Biocopea, Robin co-founded Arakis, which successfully discovered, developed and licensed a pipeline of products and was acquired by Sosei Corporation in 2005. Arakis’ pipeline was the basis for successfully raising over £50m during a five-year period. Arakis licensed its lead product to Novartis, in the largest European biotech deal in 2005, with a headline value of $325m and was subsequently sold to Sosei Corporation in the same year. Robin served on the Board of Sosei until leaving in 2008. Prior to this, Robin was at Chiros, Chiroscience and Celltech (as Preclinical Development Director). Robin’s early career was at Smith Kline and French. Robin is a chemist by background training and studied at Imperial College, London receiving his PhD in 1988.

Professor Brendan Buckley

Brendan Buckley is co-founder and non-executive Director at Open Orphan plc, the parent Company of hVIVO. Brendan was Chief Medical Officer of ICON plc until 2017, prior to which he co-founded Firecrest Clinical, a company which focused on improving the performance of clinical trial sites and in turn sold it ICON in 2011. While in ICON Brendan served as a member of ICON plc’s Executive Leadership Team and was actively involved in M&A targeting, assessment and diligence. A medical graduate of University College Cork (UCC) and a doctoral graduate in Biochemistry of Oxford University, Brendan has over 30 years’ experience in clinical research. He was a Director of the Health Products Regulatory Authority of Ireland between 2004 and 2011 and was a member of the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) from 2000-2003.

Cathal Friel

Cathal Friel is co-founder and Executive Chairman at Open Orphan plc, the parent Company of hVIVO. Cathal was co – founder and original board member of Amryt Pharma Plc, a leading European orphan drug company listed on the London Stock Exchange. Cathal established Raglan Capital in 2007. Founder and Chairman of Fastnet Oil & Gas plc which listed in 2012 and raised $50m in equity on the AIM market. Co-founder and Director of Merrion Stockbrokers in 2000 which was successfully sold for €80m in 2006.

Contact Cathal directly here: